Recent research led by Dr. André Veillette, a medical professor at the Université de Montréal and director of the Molecular Oncology Research Unit at the Montreal Clinical Research Institute (IRCM), has unveiled crucial insights into cancer treatment. Published in the journal Nature, the study reveals a significant mechanism that hinders the immune system's ability to combat cancer.
Uncovering SLAMF6's Role
The researchers discovered that SLAMF6 operates differently from other known molecules that inhibit immune responses. Unlike typical immune checkpoints that require interaction with tumor cells to diminish the body's defenses, SLAMF6 can activate independently on T cells. This self-activation sends signals that:
- weaken T cells' capacity to attack cancer cells;
- reduce the generation of robust, long-lasting T cells;
- accelerate immune exhaustion, diminishing T cells' effectiveness against tumors.
Current cancer immunotherapies, such as PD1 and PDL1 inhibitors, aim to eliminate the inhibitory signals produced by tumors. Although these treatments have benefited many patients, a notable proportion either do not respond or develop resistance over time.
Innovative Antibodies Enhance Immune Response
In response to SLAMF6's suppressive effects, Dr. Veillette and his team engineered monoclonal antibodies that prevent SLAMF6 from binding to itself and activating its inhibitory signals. Laboratory experiments yielded promising outcomes, including:
- enhanced activation of human T cells;
- increased numbers of durable immune cells;
- decreased levels of exhausted T cells;
- robust anti-tumor responses observed in murine models.
The researchers assert that these novel antibodies surpass existing strategies aimed at targeting SLAMF6, potentially laying the groundwork for a new class of cancer immunotherapies. They may offer hope particularly to patients who find no benefit from PD1 or PDL1 treatments.
The antibodies could be utilized alone or in conjunction with other therapies designed to activate the immune system. The next phase involves initiating early-stage clinical trials to assess the safety and efficacy of this treatment approach in individuals with solid tumors and blood cancers.
"The discovery by Dr. Veillette's team marks a pivotal moment in immunotherapy," stated Dr. Jean-François Côté, president and scientific director of IRCM. "By identifying an overlooked internal brake and creating antibodies to neutralize it, our researchers are presenting an innovative solution to the challenges of current treatments. This advancement reflects our strategic vision for developing precision therapeutics and brings genuine hope to numerous patients, showcasing the impact of translational research at IRCM."
Study Overview
The study titled "SLAMF6 as a drug-targetable suppressor of T cell immunity against cancer," authored by André Veillette and his colleagues, was published in Nature. The research received funding from the Canadian Institutes of Health Research (CIHR), the Terry Fox Research Institute, BioCanRx, Québec's Ministry of Economy, Innovation and Energy, and the Canadian Foundation for Innovation.